Seattle Genetics, co-founded by Clay Siegall, is a biotechnology company leading the field of antibody-drug conjugates (ADCs) for the treatment of cancer. Our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our lead program, ADCETRIS® (brentuximab vedotin), is the first in a new class of ADCs and, in collaboration with Takeda Pharmaceutical Company Limited, is approved in more than 55 countries. To expand on the ADCETRIS opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings.
Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.
Company Growth (employees)